KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions. What caught the Swiss pharma’s eye ...

Everyone knew the switch from 421a to 485x would mean fewer large multifamily projects. Turns out, it’s not as bad as expected. It’s worse. The new tax abatement has not merely reduced the number of ...

MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. The neuro-focused company is penning a strategic collaboration meant to develop new therapies for ...

Federal Reserve policymakers cut interest rates for the third straight meeting on Wednesday while signaling there may be only one cut next year as rates get closer to a neutral level. The Fed lowered ...

The new Biotech Act, presented by the European Commission, aims to set up a framework that helps biotechnology reach the market faster, improving the bloc’s competitiveness over China, and the United ...

(Nanowerk News) Scientists working to enhance brain-computer interface (BCI) technology—which allows people to control devices with their thoughts—have found they can improve the performance of ...

Zugo-cel, targeting CD19, is in an ongoing Phase 1 basket trial in autoimmune rheumatologic diseases. Preliminary clinical data from the Phase 1 study have been encouraging, and zugo-cel has been well ...

It's Fed Day, and the central bank's policymakers are unusually divided. The chances of another quarter-point cut remain high, but insight into the deep divisions within the Federal Reserve, plus how ...